The Effects of Ethanol on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ezogabine (Retigabine)

Clinical Therapeutics

Volumn 35, Issue 1, 2013, Pages 87-93

  Crean, Christopher S ^a   Tompson, Debra J ^b  

^a Valeant Pharmaceuticals International   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Ethanol; Ezogabine; Pharmacokinetics; Retigabine; Safety

Indexed keywords

ALCOHOL; RETIGABINE;

ADULT; ALCOHOL INTOXICATION; AREA UNDER THE CURVE; ARTICLE; BALANCE IMPAIRMENT; BLURRED VISION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ALCOHOL INTERACTION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; REACTION TIME;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; ATTENTION; CARBAMATES; CROSS-OVER STUDIES; DIZZINESS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ETHANOL; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENYLENEDIAMINES; POSTURAL BALANCE; PSYCHOMOTOR PERFORMANCE; REACTION TIME; VISION, OCULAR; YOUNG ADULT;

EID: 84872369573     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.12.003     Document Type: Article

References (16)

1. Blackburn-Munro G., Dalby-Brown W., Mirza N.R., et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005, 11:1-20.
2. + channels. Mol Pharmacol 2009, 75:272-280.
3. Rundfeldt C., Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000, 282:73-76.
4. + channel sensitivity to the anticonvulsant retigabine. J Neurosci 2005, 25:5051-5060.
5. Tatulian L., Delmas P., Abogadie F.C., Brown D.A. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001, 21:5535-5545.
6. Wuttke T.V., Seebohm G., Bail S., et al. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005, 67:1009-1017.
7. Brodie M.J., Lerche H., Gil-Nagel A., et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010, 75:1817-1824.
8. French J.A., Abou-Khalil B.W., Leroy R.F., et al. Randomized double-blind placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011, 76:1555-1563.
9. Porter R.J., Partiot A., Sachdeo R., et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007, 68:1197-1204.
10. Gordon E., Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001, 42:1266-1272.
11. Gale Encyclopedia of Neurological Disorders. Antiepileptic drugs, 2005 Accessed April 2, 2012. http://www.encyclopedia.com/doc/1G2-3435200036.html.
12. Ferron G.M., Paul J., Fruncillo R., et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002, 42:175-182.
13. Hempel R., Schupke H., McNeilly P.J., et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999, 27:613-622.
14. Borlak J., Gasparic A., Locher M., et al. N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism 2006, 55:711-721.
15. Knebel N.G., Grieb S., Leisenheimer S., Locher M. Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000, 748:97-111.
16. Bodd E., Gadeholt G., Christensson P.I., Mørland J. Mechanisms behind the inhibitory effect of ethanol on the conjucation of morphine in rat hepatocytes. J Pharmacol Exp Ther 1986, 239:887-890.